B型肝炎における共信号受容体調節の治療的可能性
Francesco Andreata1, Chiara Laura2, Micol Ravà1
1Division of Immunology, Transplantation, and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy.
Cell
|June 19, 2024
まとめ
慢性B型肝炎 (HBV) 感染症におけるCD8+ T細胞機能障害の逆転が鍵となる. 4-1BBとOX40共信号受容体の活性化により,抗ウイルス機能が回復し,有望な治療法となる.
科学分野:
- 免疫学
- ヘパトロジー
- ウイルス学
背景:
- CD8+ T細胞機能障害は慢性B型肝炎ウイルス (HBV) 感染の制御を損なう.
- この機能障害を逆転させる 特定の分子標的は 捉え難いままです
研究 の 目的:
- 機能不全のHBV特異性CD8+T細胞の共信号受容体発現を分析する.
- 抗ウイルス機能の回復のための共信号受容体の調節の可能性を調査する.
主な方法:
- HBV特異性CD8+T細胞における共信号受容体発現 (PD-1,CTLA-4,LAG-3,OX40,4-1BB,ICOS) の分析
- 共同抑制受容体と共同刺激受容体 (4-1BB,OX40) をブロックするインビトロ刺激アッセイ.
- 転写プロファイリングを用いたT細胞集団 (T_SL,T_RM) の特徴化.
主要な成果:
- 機能不全のCD8+T細胞は複数の共信号受容体を上調する.
- 4 - 1BBとOX40の活性化ですが,共抑制性受容体のブロックはなく,抗ウイルス効果体の機能が回復しました.
- 長期的刺激により,幹細胞 (T_SL) と組織内記憶細胞 (T_RM) を含む異質なT細胞群が生成された.
- 4 - 1BB刺激は慢性およびHBeAg+患者において有効であり,T細胞の若返りの可能性を示した.
結論:
- コシグナル伝達経路,特に4 - 1BBの活性化をターゲットにすることで,慢性HBVにおけるCD8+T細胞機能障害を逆転させることができます.
- 有効な治療には,幹細胞のようなT細胞群と効果細胞群の両方の抗ウイルス活性回復が不可欠である.
- 慢性B型肝炎患者の治療に 有望な可能性が示されています
さらに関連する動画
関連する概念動画
Interactions Between Signaling Pathways
6.3K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.3K
The JAK-STAT Signaling Pathway
8.8K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.8K
Amplifying Signals via Enzymatic Cascade
8.5K
When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
8.5K
Transducer Mechanism: Enzyme-Linked Receptors
2.4K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.4K


